Abstract:DNA polymerase theta (Pol theta), also known as DNA polymerase theta, is the member of the DNA polymerase A family and plays a crucial role in the repair of DNA double-strand breaks (DSB). Pol theta has 3 distinct structural domains: the N-terminal helicase-like domain with a conserved sequence, the C-terminal polymerase domain, and the central domain, which is a disordered sequence connecting these two regions. Notably, Pol theta is the only known polymerase in eukaryotes that possesses helicase activity. However, it is also an error-prone polymerase. When DNA DSBs occur, a specialized network consisting of at least 4 pathways, including classical-non homologous end joining (C-NHEJ), homologous recombination (HR), single-strand annealing (SSA), and alternative-end joining (Alt-EJ), is responsible for repairing DNA damage caused by DSBs. In the absence of major DNA repair pathways like HR, cells rely on Alt-EJ pathway mediated by Pol theta to repair damaged DNA and maintain genomic stability. Nevertheless, due to the low fidelity of Pol theta, Alt-EJ repair often leads to errors.Depletion of Pol theta has shown to increases DSB formation and compromise genomic stability. Conversely,overexpression of Pol theta has been associated with increases DNA damage markers and impairs cell cycle progression. As a result, the impact of Pol theta on genome stability remains controversial. Furthermore,overexpression of Pol theta is frequently observed in cancer and is associated with a characteristic mutational signature and poor prognosis. Depleting Pol theta in an HR-deficient background has been shown to impair cell viability, suggesting a synthetic lethal (SL) relationship between Pol theta and HR factors. In recent years, targeted chemotherapy drugs that inhibit tumor growth have gained significant attention. However, off-target effects and drug resistance pose challenges for clinical application, particularly with poly-ADP-ribose polymerase inhibitor (PARPi). Blocking Pol theta activity in HR-deficient tumor cells has been found to reverse PARPi resistance, making Pol theta a very promising therapeutic target in cancer treatment. The availability of crystal structures for both helicase and polymerase domain has facilitated the design of potent inhibitors of Pol theta. Currently, several highly specific and effective small molecule inhibitors targeting Pol theta, such as Novobiocin, RP-6685, and ART558, have been reported to effectively block various cancers with HR deficiency. The initial success of these inhibitors points to new directions for treating BRCA1/2-mutated tumors. Additionally, reducing the Alt-EJ repair pathway mediated by Pol theta can improve HR repair efficiency and increase the chance of exogenous gene target integration (TI),suggesting potential new applications for Pol theta inhibitors. This article reviews the recent research progress on the molecular function of Pol theta and its involvement in the Alt-EJ pathway modification mechanism, providing insights for a deeper understanding of this field.

DNA polymerase theta-mediated DNA repair is a functional dependency and therapeutic vulnerability in DNMT3A deficient leukemia cells

DNA polymerase θ protects leukemia cells from metabolically induced DNA damage

TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

Targeting DNA polymerase β elicits synthetic lethality with mismatch repair deficiency in acute lymphoblastic leukemia

3141 – LEUKEMIA-ASSOCIATED MUTATIONS IN DNMT3A MEDIATE SENSITIVITY TO REPLICATION STRESS INDUCED BY NUCLEOSIDE ANALOGS

Polθ promotes the repair of 5′-DNA-protein crosslinks by microhomology-mediated end-joining

Polθ is phosphorylated by PLK1 to repair double-strand breaks in mitosis

Abstract B004: Polymerase theta (Pol θ) is essential to repair a subset of DNA breaks in HR proficient cells

DNA Polymerase Θ: a Multifunctional and Error-prone DNA End Repair Enzyme

Structural Basis for Pol theta-Helicase DNA Binding and Microhomology-Mediated End-Joining

Human polymerase theta helicase positions DNA microhomologies for double-strand break repair

Loss of Dnmt3a impairs hematopoietic homeostasis and myeloid cell skewing via the PI3Kinase pathway

DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1

Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT 3 ( ITD )-positive leukemia cells to PARP 1 inhibitors Short title : FLT 3 and PARP 1 inhibitors against AMLs

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

Structure and Mechanism of Human DNA Polymerase Η

Cell cycle regulation of polymerase theta mediated end-joining underlies its sensitivity to loss of BLM-DNA2

Polymerase theta is a synthetic lethal target for killing Epstein-Barr virus lymphomas

DNA mismatch repair controls the mutagenicity of Polymerase ζ-dependent translesion synthesis at methylated guanines

DNA polymerase kappa stabilized by PTBP2 interacts with MRE11 and promotes genomic instability in leukemia cells

Drosophila DNA polymerase theta utilizes both helicase-like and polymerase domains during microhomology-mediated end joining and interstrand crosslink repair